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Primary sclerosing cholangitis: a pre-malignant condition. 
Abstract:  
Primary Sclerosing Cholangitis (PSC), is a chronic, progressive cholestatic liver disease with 
no known cure. It is a serious disease and with this diagnosis comes an increased risk of 
developing cancer of the gallbladder, bile ducts or primary cancer of the liver known as 
hepatocellular cancer. PSC is associated with ulcerative colitis and patients with a dual 
diagnosis will have an increased risk of developing cancer of the bowel. In addition, 
patients can die from complications from colitis or liver failure and therefore, primary 
sclerosing cholangitis can be considered a pre-malignant condition. In view of this, one of 
the key aspects in managing PSC patients is regular surveillance to observe and rapidly 
treat any developing complications. 
Primary sclerosing cholangitis (PSC) is a chronic, incurable cholestatic liver disease 
characterised by inflammation and fibrosis, leading to irregular and patchy stricturing of the 
intra and extrahepatic bile ducts (Chapman 2015; Lee and Kaplan, 1995). The disease 
progresses slowly over 10 - 15 years and will lead to cirrhosis in most patients, with the 
associated complications of portal hypertension, liver failure and premature death (Yimam 
and Bowlus 2014; Lee and Kaplan, 1995).  
In a normal liver, bile is made from the breakdown of the haem part of haemoglobin. Once 
made, bile is carried through the biliary tree into the small intestine. Bile contains bile acids 
which is crucial for the digestion and absorption of fats that contain soluble vitamins: A, D, E 
and K. Disorders that impair the production of bile result in the condition known as 
cholestasis. There are many possible causes of cholestasis with PSC being one of them. 
Aetiology 
The cause of PSC is unknown but it is linked with inflammatory bowel disease, in particular, 
ulcerative colitis (UC), suggesting an autoimmune component to this disease (Broome and 
Bergquist, 2006; Bambha et al, 2003).  It affects more males than females with a ratio of 2:1 
(Nayagam et al, 2016). Most patients present with the condition between the age of 25 – 40 
years; with a mean age of 40, but it can affect children (Chapman et al, 2010; EASL, 2009). 
According to Chapman, (2015) 75% of patients with PSC have UC and approximately 3-10% 
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of patients with a diagnosis of UC will develop PSC. Although associated as potentially an 
autoimmune condition a further theory is that PSC, with a dual diagnosis of UC, may be 
related with “leaky gut” in which the inflammatory component of UC increases disruption of 
bowel mucosa. This in turn leads to increased permeability through the bowel wall, leading 
to bacterial translocation into the portal venous system (Adams et, al 2008). Studies by 
Grant et al (2002, 2001), suggested that the circulation of lymphocytes, which originated 
from the intestine, may cause inflammation of the liver although there is no confirmed link 
to PSC at present. 
Diagnosis 
A diagnosis of PSC is made in patients with increased blood levels of alkaline phosphatase 
(ALP) and gamma-glutamyl transferase (GGT); a hallmark of PSC. In 95% of cases, these liver 
function test (LFT) readings can be between 3 to 10 times the upper limit of normal (Yiman 
and Bowlus, 2014).  If there is no other explanation for the raised LFT’s , then magnetic 
resonance cholangiopancreatography (MRCP) or endoscopic retrograde 
cholangiopancreatography (ERCP) is undertaken. If these tests reveal bile duct changes with 
multifocal strictures and dilation of segments of the bile duct, then PSC can be diagnosed, 
when other cholestatic disorders have been excluded. Throughout the disease course, it is 
acknowledged that the LFT’s can fluctuate and sometimes normalise but this will vary in 
individual patients and over time (Mendes et al, 2006). 
Many patients with PSC are initially asymptomatic and the diagnosis is made incidentally 
when liver function tests are checked and abnormal findings such as a raised ALP and GGT is 
discovered and investigated, especially in patients with pre-existing UC. It is important that 
nurses working within gastroenterology units; monitoring patients with UC are aware of the 
clinical significance of a raised ALP and GGT to either; organise further investigations and 
alert the appropriate medical team of the raised blood result. 
Symptoms of PSC 
Other clinical symptoms of PSC commonly include fatigue and frequently attributed by 
patients to busy lifestyles such as work and looking after young children. This symptom can 
often be ignored for many months or even years and it is not until other signs and 
symptoms are apparent such as: right upper quadrant abdominal discomfort, pruritis, 
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weight loss, and temperature with rigors, suggestive of inflammation of the bile ducts, that 
patients seek medical or nurse advice. Jaundice can be another symptom of PSC but is 
uncommon unless cholangiocarcinoma; a bile duct cancer, or bile duct stones are present. 
Suspicion would be roused of a possible cholangiocarcinoma or hepatocellular carcinoma 
with a sudden or further deterioration in liver function tests (LFT’s) and jaundice; with either 
of these symptoms further investigations should be undertaken to rule out carcinoma. 
Unfortunately, there is no cure for PSC and no drug treatments with proven mortality 
benefits (Nayagam et al, 2016). Evidence suggests that in symptomatic patients, from the 
time of diagnosis to death, or liver transplantation is 12-15 years (Yiman and Bowlus, 2014). 
Studies also acknowledge that patients who are symptomatic at diagnosis have a shorter 
median survival than those who are asymptomatic (Chapman, 2015).  
Small duct PSC 
There are variant forms of PSC, such as small duct PSC and this can account for up to 16% of 
the PSC population. Small duct PSC affects the very small bile ducts so makes it difficult to 
distinguish on ERCP or MRCP as both tests can look normal. Therefore, the diagnosis of 
small duct PSC (SDPSC) is made from histology from a liver biopsy and biochemically from 
the blood tests (Bjornsson et al, 2008). Evidence suggests that SDPSC has a slower disease 
progression compared to large duct PSC. Because of this, there is a decreased risk of 
cholangiocarcinoma, with an increased survival rate compared to large duct PSC. However, 
12% of SDPSC will go on to develop large duct disease (Bjornsson et al, 2008; Angulo et al, 
2002). 
Cholangitis 
PSC causes multifocal stricturing of the bile ducts which in turn can disrupt the production 
and flow of bile. This can lead to the development of cholestasis and cholangitis. Cholangitis 
is an infection of the bile ducts, which has a high morbidity and mortality and this increases 
with the age of the patient (Kumar and Clark, 2012). According to Chapman, (2015) attacks 
of cholangitis in PSC patients are uncommon and tend to occur after surgical 
instrumentation such as endoscopic retrograde cholangiopancreatography (ERCP). 
Consideration should also be given to patients with suspected or known PSC who undergo a 
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liver biopsy. These patients may require prophylactic antibiotics to be administered to 
prevent cholangitis.  
Drug treatment 
Ursodeoxycholic acid (UDCA) is often prescribed by clinicians as it can improve ALP levels 
when prescribed at a dose of 13-15mg/kg. Nevertheless, there is no conclusive proof that it 
alters disease progression even if ALP levels fall (Lindor, 1997); although there is some 
evidence to suggest it has a protective mechanism in the development of bowel cancer 
(Pardi, et al, 2003). A meta-analysis on the use of ursodeoxycholic acid in PSC found that at 
the standard or a higher dose presented no real difference in the risk of developing a 
cholangiocarcinoma or decreased mortality (Triantos et al, 2011).  Published Guidelines by 
the American Association for the Study of the Liver (AASLD; Chapman et al, 2010) advocate 
not using ursodeoxycholic acid for the treatment of PSC. The European Association for the 
study of the Liver (EASL, 2009) made no recommendations for its use in the treatment of 
PSC due to the limited available research. 
Cholangiocarcinoma 
Approximately 37% of PSC patients will die from liver failure due to cirrhosis and a further 
10 - 30% may develop cholangiocarcinoma. The risk of developing a cholangiocarcinoma 
increases with the length of time diagnosed with PSC (Claessen et al, 2009). 50% of 
cholangiocarcinoma’s are diagnosed within the first year of PSC diagnosis (EASL, 2009). 
Unfortunately, survival after diagnosis of a cholangiocarcinoma is poor even if surgery is 
performed; with less than a 20% survival rate after 3 years (Rosen and Nagorney, 1991). 
Distinguishing between benign strictures of the bile duct or a cholangiocarcinoma can be 
difficult and by the time cholangiocarcinoma is diagnosed it may already be at an advanced 
stage; with deranged LFT’s, where palliative chemotherapy, surgical resection or transplant 
is no longer an option. 
A study by (Bergquist, et al., 2002) found that over 13% of a 600 cohort of PSC patients 
developed either a cholangiocarcinoma, hepatocellular carcinoma or gallbladder cancer. 
This equates to a risk of 161 times greater than the general population. Patients with a dual 
diagnosis of PSC and UC may develop complications from colitis or develop colonic cancer, 
both of which can lead to patient death. Therefore, PSC can be classed as a pre-malignant 
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condition (Chapman, 2015). For this reason, nurses caring for patients with this illness 
require an understanding of the disease process to appreciate the seriousness of the 
condition and its associated complications, enabling early detection and rapid instigation of 
medical or surgical treatments. 
Bowel Cancer and surveillance 
PSC patients with a dual diagnosis of UC are at risk of developing bowel cancer. According to 
a seminal study by Shetty et al., (1999) 76% of bowel cancers were found on the right side of 
the colon in patients with the dual diagnosis. This and other evidence regarding the 
increased risk colorectal cancer development has led to PSC guidance being produced by 
AASLD (Chapman et al, 2010) which recommends a full colonoscopy with biopsies for all 
newly diagnosed patients as well as 1-2 yearly surveillance colonoscopies thereafter. 
Gallbladder cancer and surveillance 
PSC patients have an increased risk of developing gallbladder cancer especially if gallbladder 
polyps are present (Said et al., 2008; Lewis et al., 2007; Buckles et al., 2002). Both the AASLD 
and European Association for the Study of the Liver (EASL) guidelines recommend annual 
gallbladder surveillance in the form of an abdominal ultrasound (Chapman et al, 2010; EASL, 
2009). Cholecystectomy is recommended if any gallbladder polyps are detected, regardless 
of the size. PSC patients who have undergone a cholecystectomy will no longer require the 
annual gallbladder surveillance 
Hepatocellular Cancer 
Cirrhosis of the liver can lead to the development of hepatocellular cancer (HCC). However, 
the risk of developing a HCC is dependent on the underlying cause of the liver disease. In a 
retrospective analysis of 119 PSC cirrhotic patients, no cases of HCC were identified (Zenouzi 
et al., 2014) Currently, there is no recommendation for screening in PSC cirrhotic patients. 
Although this may be the case, it can be easier for nurses, who are often tasked with the job 
of surveillance monitoring, to organize 6 monthly surveillance ultrasound scans on all 
cirrhotic patients, rather than singling out specific cohorts. This is especially pertinent since 
NICE (2017) have released the Liver Disease quality standard (QS152) that, “adults with 
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cirrhosis are offered 6-monthly surveillance for hepatocellular carcinoma”, although it is 
acknowledged that this was not inclusive of autoimmune disease. 
 Fat soluble vitamin deficiencies 
As PSC progresses, patients can develop deficiencies in fat-soluble vitamins such as A, D E 
and K, due to the disruption in the production and flow of bile. This can cause further 
complications associated with vitamin deficiencies. All patients diagnosed with PSC should 
be offered a dual energy X-ray absorptiometry scan (DEXA scan). This is a special type of X-
ray that measures bone mineral density (BMD) to diagnose osteopenia or osteoporosis; a 
complication of inadequate Vitamin D intake. DEXA scans should be repeated every 2-5 
years depending on the initial result. If osteopenia is diagnosed on the initial DEXA scan then 
Adcal-D3, 2 tablets, once daily should be prescribed as a prophylactic measure against the 
development of osteoporosis. Adcal-D3 contains vitamin D and calcium and should not be 
prescribed in patients with a known history of renal stones as this can exacerbate stone 
formation. If osteoporosis is diagnosed, then bisphosphonates are prescribed. If the patient 
is unable to tolerate oral tablets or has known varices, then bisphosphonates should be 
administered intravenously. This is recommended as oral bisphosphonates are known to 
cause mucosal irritation of the gastro intestinal (GI) tract causing nausea , vomiting, 
epigastric pain and dyspepsia (De Groen et al., 1996) thereby increasing the risk of GI 
haemorrhage.  
Administration of bisphosphonates 
There are strict instructions for the correct oral administration of bisphosphonates to 
reduce the risk of GI complications.  These instructions have been issued by Medicines and 
Healthcare Products Regulatory Agency (MHRA, 2014) and are also found within leaflets 
issued with the medication. It is of upmost importance that patients are advised on how to 
correctly take these medications to avoid serious side effects. Health care professionals 
Nurses monitoring, or looking after patients on gastro/hepatology wards should be aware of 
the correct route of administration of bisphosphonates and can advise accordingly; 
reiterating the fact that no other food or medicines should be taken for an hour after 
ingestion of biphosphonates. This is especially pertinent to prescribers, with regards to the 
timing of medications for inpatients.  
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Monitoring for vitamin deficiencies 
In view of potential vitamin deficiencies, further monitoring of the other fat soluble vitamin 
levels such as Vitamin A, E and K should be undertaken at least annually and 
supplementation prescribed if required. Clotting disorders due to a deteriorating liver 
function or a deficiency in vitamin K, especially if jaundice is present, should also be 
considered and monitored closely. If clotting is normal, then a clotting screen should be 
checked at least yearly and introduced more frequently if abnormalities are detected. 
Immunoglobulin G4 related sclerosing cholangitis 
A separate entity called, Immunoglobulin G4 (IgG4) related sclerosing cholangitis can closely 
mimic PSC but unlike PSC can be treated with steroids and is reversible (Zen, et al, 2004). 
Therefore, correct diagnosis is important for the correct therapeutic treatment. IgG4 is a 
multisystem disorder which can affect pancreas, salivary glands, aorta, thyroid, kidneys, 
lungs and the liver. IgG4 levels can be raised in PSC but are seen at higher levels in IgG4 
sclerosing cholangitis. Therefore, IgG4 levels should be checked to help differentiate 
between the two conditions. The diagnosis of IgG4 disease can be made by taking a good 
history; being alert to other symptoms suggestive of a multi system involvement and 
checking IgG4 level. 
Transplantation 
In patients in the advanced stages of PSC, a liver transplant is the only treatment option. 
Liver transplant is also offered to patients with intractable pruritis or recurrent cholangitis. 
Unfortunately, PSC can reoccur in the transplanted liver with studies showing between a 10-
30% recurrence rate within 5 years (Chapman, 2015; Charatcharenwitthaya and Lindor, 
2008). Post-transplant, there is a five year survival rate of around 75-80%. In patients with a 
dual diagnosis of UC it is recognised that the UC may deteriorate and that a further 5-10% 
may develop colorectal cancer (Charatcharenwitthaya and Lindor, 2008). Annual 
colonoscopy surveillance should continue post-transplant. 
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Summary of diagnosis and treatment 
 AASLD Recommendations 
(Chapman et al ., 2009) 
EASL Recommendations 
(EASL, 2009) 
 
Diagnosis Raised ALP and GGT when 
ERCP and MRCP show bile 
duct changes of multifocal 
strictures and dilatations 
(beading) 
“ 
Patients with normal 
ERCP/MRCP but raised 
ALP/GGT  
Liver biopsy to exclude 
SDPSC or autoimmune 
hepatitis overlap 
“ 
Exclude IgG4 disease Measure IgG$ levels “ 
Autoantibodies No role for diagnosing PSC “ 
Bone scan On diagnosis 
Then 2-3 yearly 
No specific 
recommendation 
osteopenia Calcium 1-1.5g and Vitamin 
D 1000iu daily 
No specific 
recommendation 
osteoporosis Biphosphonate and calcium 
and vitamin D supplements 
No specific 
recommendation 
Osteoporosis and varices Parenteral preparation 
rather than oral 
No specific 
recommendation 
New diagnosis PSC no 
History IBD 
Full colonoscopy Full colonoscopy 
IBD and PSC Full colonoscopy 1-2 yearly 
intervals 
Annual colonoscopy 
USS Annual – surveillance mass 
lesions of gallbladder.  
If found - cholecystectomy 
Annual – surveillance mass 
lesions of gallbladder.  
If found – cholecystectomy 
CCA If no cirrhosis – surgical 
resection or transplant 
 
UDCA  Recommend against the use Although improves LFT’s no 
benefit on survival. No 
recommendation for 
general use of UDCA 
UDCA for chemoprevention 
of colorectal cancer 
Recommend against the use Limited evidence but may 
be considered in those with 
a strong family history, 
previous colorectal cancer 
or longstanding extensive 
colitis 
Immunosuppressants and 
steroids 
Recommend the use in 
autoimmune hepatitis 
overlap 
Role in PSC AIH overlap  
None can be recommended 
for PSC alone 
Pruritis Antihistamines No specific 
recommendation 
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Cholestyramine 4g up 16 g 
daily 
Rifampicin 150mg -300mg 
(BD) 
Opiate antagonist 
(Naltrexone) 50mg daily 
Sertraline 75-100mg daily 
Liver transplant Advanced liver disease Late stage PSC 
Recurrent bacterial 
cholangitis 
Cholangicyte dysplasia 
 
 
Summary of surveillance 
 All PSC patients should have regular surveillance in the form of: 
 Oesophago-gastro-duodenoscopy (OGD) for varices surveillance if cirrhotic 
 6 monthly ultrasound scans of the liver if cirrhotic for hepatocellular carcinoma  
 Any sudden deterioration in LFT’s - surveillance ultrasound scan of the liver for 
cholangiocarcinoma or hepatocellular carcinoma. 
 Annual ultrasound scan for the development of gallbladder cancers  
 Annual colonoscopies for bowel cancer surveillance 
 Annual blood test monitoring for vitamin deficiencies and increased in frequency if 
abnormalities detected 
 DEXA scan on diagnosis of PSC then 2-5 yearly for the surveillance of osteopenia or 
osteoporosis. 
 
Conclusion  
PSC is a serious disease, with many associated complications and as such, can be considered 
a premalignant condition. It is important for all health professionals; especially those who 
look after PSC patients on the wards, or on an outpatient basis, are aware of the signs and 
symptoms of disease progression and complications associated with PSC. With this 
knowledge, it will enable health care professionals to offer the patient correct advice, 
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assistance, timely surveillance and support when needed as well as expediting treatment 
and/or investigations when required in a judicious manner. 
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